$SDGR News

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

UBS Maintains Neutral on Schrodinger, Raises Price Target to $21

Keybanc Maintains Overweight on Schrodinger, Raises Price Target to $32

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth

TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $31

BMO Capital Maintains Outperform on Schrodinger, Raises Price Target to $30

Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued View

Schrodinger Stock Has Technical Strength as It Hits New 2-Year Highs

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Schrödinger Announces Formation Of Tectora, New Biotechnology Company; Tectora Secures $55M Series A Investment From NEA And RA Capital Management

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrodinger: The Software Business Is Stronger Than It Looks

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. 2026 Q2 - Results - Earnings Call Presentation

Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ...